- Home
- YGMZ vs STRO Comparison
YGMZ vs STRO Comparison
Compare YGMZ & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- STRO
- Stock Information
- Founded
- YGMZ 2002
- STRO 2003
- Country
- YGMZ China
- STRO United States
- Employees
- YGMZ N/A
- STRO N/A
- Industry
- YGMZ Transportation Services
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YGMZ Consumer Discretionary
- STRO Health Care
- Exchange
- YGMZ Nasdaq
- STRO Nasdaq
- Market Cap
- YGMZ 72.3M
- STRO 69.1M
- IPO Year
- YGMZ 2020
- STRO 2018
- Fundamental
- Price
- YGMZ $0.89
- STRO $0.98
- Analyst Decision
- YGMZ
- STRO Hold
- Analyst Count
- YGMZ 0
- STRO 7
- Target Price
- YGMZ N/A
- STRO $1.97
- AVG Volume (30 Days)
- YGMZ 32.5K
- STRO 548.4K
- Earning Date
- YGMZ 01-01-0001
- STRO 08-07-2025
- Dividend Yield
- YGMZ N/A
- STRO N/A
- EPS Growth
- YGMZ N/A
- STRO N/A
- EPS
- YGMZ N/A
- STRO N/A
- Revenue
- YGMZ $40,429,750.00
- STRO $104,473,000.00
- Revenue This Year
- YGMZ N/A
- STRO $65.42
- Revenue Next Year
- YGMZ N/A
- STRO N/A
- P/E Ratio
- YGMZ N/A
- STRO N/A
- Revenue Growth
- YGMZ N/A
- STRO N/A
- 52 Week Low
- YGMZ $0.63
- STRO $0.52
- 52 Week High
- YGMZ $1.77
- STRO $4.80
- Technical
- Relative Strength Index (RSI)
- YGMZ 51.72
- STRO 59.92
- Support Level
- YGMZ $0.75
- STRO $0.95
- Resistance Level
- YGMZ $1.06
- STRO $1.18
- Average True Range (ATR)
- YGMZ 0.15
- STRO 0.09
- MACD
- YGMZ 0.03
- STRO 0.02
- Stochastic Oscillator
- YGMZ 61.44
- STRO 46.57
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. The segments of the company are the trucking business, car owner services business, and liquor distribution business.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.